SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Akpinar G)
 

Sökning: WFRF:(Akpinar G) > Cross-reactive EBNA...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005256naa a2200505 4500
001oai:DiVA.org:uu-506588
003SwePub
008230628s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:152861661
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5065882 URI
0247 a https://doi.org/10.1126/sciadv.adg30322 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1528616612 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Thomas, Olivia G.u Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
2451 0a Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis
264 1b American Association for the Advancement of Science (AAAS),c 2023
338 a electronic2 rdacarrier
520 a Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, for which and Epstein-Barr virus (EBV) infection is a likely prerequisite. Due to the homology between Epstein-Barr nuclear antigen 1 (EBNA1) and alpha-crystallin B (CRYAB), we examined antibody reactivity to EBNA1 and CRYAB peptide libraries in 713 persons with MS (pwMS) and 722 matched controls (Con). Antibody response to CRYAB amino acids 7 to 16 was associated with MS (OR = 2.0), and combination of high EBNA1 responses with CRYAB positivity markedly in-creased disease risk (OR = 9.0). Blocking experiments revealed antibody cross-reactivity between the homolo-gous EBNA1 and CRYAB epitopes. Evidence for T cell cross-reactivity was obtained in mice between EBNA1 and CRYAB, and increased CRYAB and EBNA1 CD4+ T cell responses were detected in natalizumab-treated pwMS. This study provides evidence for antibody cross-reactivity between EBNA1 and CRYAB and points to a similar cross-reactivity in T cells, further demonstrating the role of EBV adaptive immune responses in MS development.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
7001 a Bronge, Mattiasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Tengvall, Katarina,d 1980-u Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Science for Life Laboratory, SciLifeLab,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut0 (Swepub:uu)katst103
7001 a Akpinar, Birceu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Nilsson, Ola B.u Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Holmgren, Eriku Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Hessa, Tarau Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Gafvelin, Gurou Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Khademi, Mohsenu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut
7001 a Alfredsson, Larsu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.;Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden.4 aut
7001 a Martin, Rolandu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.;Univ Zurich, Inst Expt Immunol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.4 aut
7001 a Guerreiro-Cacais, Andre Ortliebu Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut
7001 a Grönlund, Hansu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 aut
7001 a Olsson, Tomasu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut
7001 a Kockum, Ingridu Karolinska Institutet,Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Neuroimmunol Unit, S-17176 Stockholm, Sweden.4 aut
7102 a Karolinska Institutetb Karolinska Inst, Ctr Mol Med, Dept Clin Neurosci, Therapeut Immune Design, S-17176 Stockholm, Sweden.4 org
7730 t Science Advancesd : American Association for the Advancement of Science (AAAS)g 9:20q 9:20x 2375-2548
8564 u https://doi.org/10.1126/sciadv.adg3032y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1776664/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-506588
8564 8u https://doi.org/10.1126/sciadv.adg3032
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:152861661

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy